Últimas noticias sobre Trinity Biotech (NASDAQ:TRIB) Bolsa

Trinity Biotech

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Trinity Biotech plc - American Depositary Shares

Trinity Biotech PLC

Tribe - United States Dollar

XINDA INTL CORP by Xinda International Corp.

Tribal Rides International Corp

TRIBE PPTY TECHNOLOGIES by Tribe Property Technologies Inc.

Tribe Property Technologies Inc

Tribeca Resources Corp

Earnings

Earnings Beats

Earnings Misses

News

TRIB

Trinity Biotech Q4 EPADS $(0.1279) Beats $(0.28) Estimate, Sales $15.86M Miss $16.00M Estimate

General

Trinity Biotech Receives Non-Compliance Notice From Nasdaq Global Select Regarding Requirement For Minimum Market Value Of Publicly Held Shares And Nasdaq Minimum Bid Price Requirement

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring ("CGM") technology with the appointment of Barclays Capital Inc. ("Barclays") as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company's increased focus on its CGM technology as part of its broader transformation plan.
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech's board and management have determined that CGM technology and related data driven insights will be the Company's primary strategic focus moving forward.&nbsp;
The successful execution of Trinity Biotech's comprehensive transformation plan is expected to drive near-term profitability improvements, creating potential opportunities to optimize its portfolio and support CGM-related growth. As part of this effort, Barclays is now actively assessing how the Company's existing businesses can best align with this new strategic direction.&nbsp;

Trinity Biotech Taps Barclays to Drive Strategic Shift Toward Glucose Monitoring Tech

Financing

Trinity Biotech Announces Additional $4M Funding

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than 50% improvement in Mean Absolute Difference (MAD) with Trinity Biotech's redesigned CGM sensor compared to the previously marketed Waveform product. The first 24 hours of CGM wear have been a persistent weak spot across the industry, with sensor accuracy often fluctuating due to the body's natural response to insertion. These advancements promise to address a key pain point for users, as inconsistent glucose readings on the first day of wear have historically led to user frustration and safety concerns.

Trinity Biotech's Latest CGM Trial Sets New Benchmark For Accuracy, Reliability, And User Experience

<h3>Gainers</h3>
<ul>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) shares rose 97.2% to $5.74 during Thursday's pre-market session. The company's market cap stands at $50.1 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) shares rose 64.27% to $0.63. The market value of their outstanding shares is at $3.8 million. </li>
<li>Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) stock moved upwards by 52.09% to $39.12. The company's market cap stands at $577.1 million. </li>
<li>Processa Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares moved upwards by 21.72% to $0.72. The market value of their outstanding shares is at $2.6 million. </li>
<li>Inventiva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVA#NASDAQ">IVA</a>) stock moved upwards by 12.6% to $2.59. The market value of their outstanding shares is at $135.6 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 11.53% to $1.45. The market value of their outstanding shares is at $6.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) stock fell 75.6% to $3.22 during Thursday's pre-market session. The market value of their outstanding shares is at $148.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares declined by 32.49% to $2.12. The company's market cap stands at $8.4 million. </li>
<li>Kiniksa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNSA#NASDAQ">KNSA</a>) shares fell 12.83% to $18.01. The company's market cap stands at $1.3 billion. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock decreased by 11.37% to $1.17. The company's market cap stands at $32.1 million. </li>
<li>Opthea (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPT#NASDAQ">OPT</a>) stock decreased by 11.25% to $4.5. The market value of their outstanding shares is at $692.4 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) shares declined by 10.17% to $8.4. The company's market cap stands at $524.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CRGX

IMNM

KNSA

NAOV

PCSA

PLRZ

SLXN

TECX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares rose 76.9% to $0.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $20.3 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock rose 57.77% to $2.13. The market value of their outstanding shares is at $8.5 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) stock moved upwards by 28.32% to $0.99. The market value of their outstanding shares is at $2.2 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock increased by 16.41% to $1.56. The company's market cap stands at $6.0 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) shares increased by 13.89% to $1.18. The market value of their outstanding shares is at $39.9 million. </li>
<li>Tonix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) stock moved upwards by 11.95% to $0.52. The company's market cap stands at $96.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares decreased by 26.2% to $0.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $1.8 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) shares decreased by 24.59% to $1.81. The company's market cap stands at $128.9 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock fell 19.3% to $0.05. The market value of their outstanding shares is at $5.1 million. </li>
<li>Pulmonx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) shares declined by 15.71% to $5.1. The company's market cap stands at $201.3 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock declined by 15.45% to $1.15. The market value of their outstanding shares is at $31.6 million. </li>
<li>Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) shares fell 10.55% to $19.26. The company's market cap stands at $21.8 billion. The company's, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

EYEN

LUNG

OCEA

OKYO

SXTP

TEVA

TNXP

ZNTL

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) stock increased by 112.1% to $1.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.9 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock increased by 62.84% to $1.35. The company's market cap stands at $2.7 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares rose 61.86% to $1.23. The market value of their outstanding shares is at $33.8 million. </li>
<li>Hepion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock rose 32.84% to $0.22. The market value of their outstanding shares is at $1.5 million. </li>
<li>Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) stock increased by 19.85% to $25.47. The market value of their outstanding shares is at $3.2 billion. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) shares rose 13.78% to $0.99. The market value of their outstanding shares is at $23.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock decreased by 69.2% to $0.45 during Tuesday's pre-market session. </li>
<li>Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) shares fell 63.54% to $0.82. The market value of their outstanding shares is at $31.4 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares declined by 44.73% to $2.41. The market value of their outstanding shares is at $22.2 million. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) shares declined by 20.78% to $2.44. The market value of their outstanding shares is at $120.9 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) shares fell 16.71% to $0.54. The market value of their outstanding shares is at $4.4 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares declined by 12.5% to $1.47. The market value of their outstanding shares is at $257.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKYA

HEPA

LPTX

ONCO

SABS

SGRY

STSS

TVGN

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Trinity Biotech Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its continuous <a href="https://www.benzinga.com//node/43262188">glucose monitoring (CGM) system.</a>
The Details: The trial results indicated a 25% to 30% improvement in accuracy over earlier CGM sensors and revealed improvements in clarity compared to previous models.
The pre-pivotal clinical trial involved 30 participants, most of whom had Type 1. The trial evaluated modifications made by Trinity&#8217;s Research and Development team to the sensor technology acquired from Waveform Technologies, Inc.
&#8220;We believe that our patented technology—featuring a modular, eco-friendly design and cutting-edge sensor performance—represents a paradigm shift in the CGM market, which is projected to exceed&nbsp;$20 billion&nbsp;by 2029. We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,&#8221; said John Gillard, CEO of Trinity Biotech.
The company plans to complete clinical trials on device improvements and aims for regulatory approval in the European Union by 2025 and the United States by 2026.
Related Link: <a href="https://www.benzinga.com/news/25/01/43267885/sysco-posts-q2-earnings-above-street-view-as-operating-income-improves">Sysco Posts Q2 Earnings Above Street View As Operating Income Improves</a>
TRIB Price Action: At the time of writing, Trinity shares are trading 55.4% higher at $1.185, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

What's Going On With Trinity Biotech Shares Tuesday?

WIIM

Trinity Biotech shares are trading higher after the company announced results from its pre-pivotal clinical trial for its continuous glucose monitoring system.

Trinity Biotech Posts Productive Results From Pre-Pivotal Trial Of Continuous Glucose Monitoring (CGM) Tech

<h3>Gainers</h3>
<ul>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock moved upwards by 25.1% to $0.73 during Wednesday's pre-market session. The company's market cap stands at $3.6 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock rose 21.71% to $0.74. The company's market cap stands at $29.9 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock increased by 14.21% to $0.92. The company's market cap stands at $25.3 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares increased by 14.2% to $5.95. The company's market cap stands at $66.0 million. </li>
<li>Evaxion Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) stock moved upwards by 12.54% to $3.05. The company's market cap stands at $17.8 million. </li>
<li>Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) shares increased by 12.53% to $3.06. The market value of their outstanding shares is at $114.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lisata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) shares declined by 19.2% to $3.15 during Wednesday's pre-market session. The market value of their outstanding shares is at $26.4 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock declined by 14.57% to $0.88. The market value of their outstanding shares is at $3.2 million. </li>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock decreased by 11.82% to $1.12. The company's market cap stands at $51.2 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) shares fell 11.75% to $2.78. The market value of their outstanding shares is at $3.7 million. </li>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock decreased by 9.84% to $0.13. The market value of their outstanding shares is at $4.8 million. </li>
<li>Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) stock fell 9.49% to $10.21. The company's market cap stands at $263.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTNM

DWTX

EVAX

HSDT

LSTA

MTNB

NTRB

VINC

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has entered into amended agreements with its primary lender, Perceptive Advisors. These strategic amendments provide additional liquidity, further enhancing the Company's near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative continuous glucose monitoring (CGM) technology.
Under the terms of the agreements, a deferred consideration payment of $5 million related to the acquisition of the biosensor assets of Waveform Technologies has been extended to November 2025, offering the Company greater financial flexibility. In addition, further additional liquidity in the amount of approximately $5.5 million has been provided to Trinity Biotech through a combination of cash and payment-in-kind interest, strengthening liquidity during this pivotal period of transformation. As part of the agreement, Trinity Biotech has granted Perceptive Advisors 1.5 million additional warrants to purchase the Company's ADS, and repriced its existing ADS warrants at an exercise price of $0.80 per ADS, reinforcing the ongoing partnership between the two entities.

Offerings

Management

Trinity Biotech Amends Credit Agreement With Perceptive Advisors To Boost Liquidity And Support Transformation Plan; Secures $5.5M In Additional Funding, Extends $5M Payment To 2025, And Issues 1.5M New Warrants At $0.80 Exercise Price

Trinity Biotech plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.

Biotech

Trinity Biotech Receives Early Approval From The WHO To Begin Offshore Manufacturing Of TrinScreen HIV & Uni-Gold HIV

Guidance

Trinity Biotech Reiterates Guidance To Achieve 2024 Sales Revenue For TrinScreen HIV Of Approximately $10M

Trinity Biotech Reiterates Guidance To Achieve $20M Of Annualized Run-rate EBITDASO On Annualized Run-rate Revenues Of $75M By Q2 2025

Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) reported quarterly losses of $(0.46) per ADS which beat the analyst consensus estimate of $(0.54) by 14.81 percent. This is a 47.73 percent increase over losses of $(0.88) per ADS from the same period last year. The company reported quarterly sales of $15.15 million which missed the analyst consensus estimate of $16.50 million by 8.17 percent. This is a 3.24 percent increase over sales of $14.68 million the same period last year.

Trinity Biotech Q3 2024 GAAP EPADS $(0.46) Beats $(0.54) Estimate, Sales $15.15M Miss $16.50M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sigma Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGML#NASDAQ">SGML</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $72.08 million. 
• Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) is projected to report quarterly loss at $0.54 per share on revenue of $16.50 million. 
• Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) is projected to report quarterly loss at $0.13 per share on revenue of $9.90 million. 
• Aegon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEG#NYSE">AEG</a>) is projected to report earnings for its third quarter. 
• Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) is expected to report earnings for its third quarter. 
• WiSA Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>) is likely to report quarterly loss at $0.68 per share on revenue of $1.00 million. 
• AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is likely to report quarterly loss at $0.10 per share on revenue of $20 thousand. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $87.84 million. 
• RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $105.08 million. 
• Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is projected to report quarterly earnings at $2.10 per share on revenue of $33.95 billion. 
• Spectrum Brands Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $746.54 million. 
<h3>Companies Reporting After The Bell</h3>
• Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) is likely to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BABA

BPTH

DGHI

NEXN

NGNE

SGML

WISA

Earnings Scheduled For November 15, 2024

Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) will release its quarterly earnings report on Friday, 2024-11-15. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Trinity Biotech to report an earnings per share (EPS) of $-0.54.
The market awaits Trinity Biotech's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Here's a look at Trinity Biotech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td>-0.60</td>
<td>-0.75</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.71</td>
<td>-0.37</td>
<td>-0.72</td>
<td>-0.88</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-9.0%</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Trinity Biotech Shares</h3>
Shares of Trinity Biotech were trading at $1.55 as of November 12. Over the last 52-week period, shares are down 18.95%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/TRIB/earnings">To track all earnings releases for Trinity Biotech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Trinity Biotech's Quarterly Earnings

Trinity Biotech Regains Nasdaq Compliance With Minimum Market Value Requirement

Health Care

Press Releases

Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

Trinity Biotech Announces Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Transformation Plan

Trinity Biotech Announces Breakthrough Results From Pre-Pivotal Trial of Disruptive Continuous Glucose Monitoring (CGM) Technology

Stocks Under $2 to Watch in February 2025: TRIB, MODD, PNPN.V, BACK – More Inside!

Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029

Trinity Biotech Reports Landmark First-Day Accuracy Gains in CGM Pre-Pivotal Trial

Trinity Biotech Announces Additional Funding To Support Transformation Plan & Continued Development of the Company's Continuous Glucose Monitoring Technology

Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process

Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares and Nasdaq Minimum Bid Price Requirement

Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024 Financial Results & Provides a Business Update

Comments

Trinity Biotech

Noticias

Últimas noticias sobre Trinity Biotech (NASDAQ:TRIB) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL